Derek Allan Prater

Title: **Derek Allan Prater: Innovator in Pharmaceutical Formulations**

Introduction

Derek Allan Prater is a prominent inventor based in Cambridge, GB, known for his significant contributions to pharmaceutical formulations, particularly in the field of sustained and delayed release medication. With a remarkable portfolio of 37 patents, Prater has established himself as a key player in the healthcare innovation landscape.

Latest Patents

Two of his latest patents exemplify his ingenuity in creating advanced pharmaceutical solutions. The first patent focuses on "Oxycodone formulations," directed towards sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof. This invention boasts a mean C/Coxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients. The second patent pertains to "Delayed release pharmaceutical formulations," where the delivery of a drug is regulated to ensure a delay before release post-administration. This is achieved by formulating the drug with a disruption agent to create a core, which is then coated with a regulatory membrane featuring a water-soluble gel-forming polymer and a water-insoluble film-forming polymer.

Career Highlights

Throughout his career, Derek has worked with reputable companies, notably Euro-Celtique S.A. and Purdue Pharma L.P., where he has applied his expertise and research to develop cutting-edge pharmaceutical products. His work has contributed significantly to the field, furthering advancements in drug delivery mechanisms and patient care.

Collaborations

Prater's journey has also seen him collaborate with notable professionals such as Stewart Thomas Leslie and Ronald Brown Miller. These partnerships have amplified his research capabilities, leading to innovative outcomes that enhance drug formulation technologies.

Conclusion

Derek Allan Prater's dedication to pharmaceutical innovation is evident through his extensive patent portfolio and collaborations. His contributions have not only advanced the field of drug delivery but have also improved the treatment outcomes for patients requiring sustained and delayed release medications. As the industry moves forward, Prater's work will undoubtedly serve as a foundation for future advancements in pharmaceutical science.